donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > FNCH Finch Therapeutics > Detailed Quotes

FNCH Finch Therapeutics

2.410
+0.150+6.64%
Close 08/08 16:00 ET
2.41000.00%
Post Mkt Price 08/08 17:17 ET
High
2.560
Open
2.380
Turnover
115.82K
Low
2.180
Pre Close
2.260
Volume
47.43K
Market Cap
114.62M
P/E(TTM)
Loss
52wk High
17.390
Shares
47.56M
P/E(Static)
Loss
52wk Low
1.712
Float Cap
54.02M
Bid/Ask %
0.00%
Historical High
22.500
Shs Float
22.42M
Volume Ratio
0.92
Historical Low
1.712
Dividend TTM
--
Div Yield TTM
--
P/B
0.64
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.21%
Amplitude
16.81%
Avg Price
2.441
Lot Size
1
Float Cap
54.02M
Bid/Ask %
0.00%
Historical High
22.500
Shs Float
22.42M
Volume Ratio
0.92
Historical Low
1.712
Dividend TTM
--
P/B
0.64
Dividend LFY
--
Turnover Ratio
0.21%
Amplitude
16.81%
Avg Price
2.441
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company’s lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn’s disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
CEO: Smith Ph.D., Mark Burnham
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...